Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Statistical Interactions from a Growth Curve Perspective.

Devlin SM, Satagopan JM.

Hum Hered. 2016;82(1-2):21-36. doi: 10.1159/000477125. Epub 2017 Jul 26.

2.

A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups.

Satagopan JM, Iasonos A, Kanik JG.

Data Brief. 2017 May 5;12:667-675. doi: 10.1016/j.dib.2017.05.005. eCollection 2017 Jun.

3.

Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.

Satagopan JM, Iasonos A.

Contemp Clin Trials. 2017 Dec;63:40-50. doi: 10.1016/j.cct.2017.02.007. Epub 2017 Feb 22.

PMID:
28254404
4.

The study of nevi in children: Principles learned and implications for melanoma diagnosis.

Scope A, Marchetti MA, Marghoob AA, Dusza SW, Geller AC, Satagopan JM, Weinstock MA, Berwick M, Halpern AC.

J Am Acad Dermatol. 2016 Oct;75(4):813-823. doi: 10.1016/j.jaad.2016.03.027. Epub 2016 Jun 17. Review.

5.

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A, Chapman PB, Satagopan JM.

Clin Cancer Res. 2016 May 1;22(9):2114-20. doi: 10.1158/1078-0432.CCR-15-2517. Review.

6.

Bayes and empirical Bayes methods for reduced rank regression models in matched case-control studies.

Satagopan JM, Sen A, Zhou Q, Lan Q, Rothman N, Langseth H, Engel LS.

Biometrics. 2016 Jun;72(2):584-95. doi: 10.1111/biom.12444. Epub 2015 Nov 17.

7.

Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment.

Satagopan JM, Iasonos A, Zhou Q.

Genet Epidemiol. 2015 Nov;39(7):509-17. doi: 10.1002/gepi.21917. Epub 2015 Sep 9.

8.

Predictors and long-term reproducibility of urinary phthalate metabolites in middle-aged men and women living in urban Shanghai.

Starling AP, Engel LS, Calafat AM, Koutros S, Satagopan JM, Yang G, Matthews CE, Cai Q, Buckley JP, Ji BT, Cai H, Chow WH, Zheng W, Gao YT, Rothman N, Xiang YB, Shu XO.

Environ Int. 2015 Nov;84:94-106. doi: 10.1016/j.envint.2015.07.003. Epub 2015 Aug 7.

9.

Sunburn, sun exposure, and sun sensitivity in the Study of Nevi in Children.

Satagopan JM, Oliveria SA, Arora A, Marchetti MA, Orlow I, Dusza SW, Weinstock MA, Scope A, Geller AC, Marghoob AA, Halpern AC.

Ann Epidemiol. 2015 Nov;25(11):839-43. doi: 10.1016/j.annepidem.2015.05.004. Epub 2015 May 23.

10.

Statistical interactions and Bayes estimation of log odds in case-control studies.

Satagopan JM, Olson SH, Elston RC.

Stat Methods Med Res. 2017 Apr;26(2):1021-1038. doi: 10.1177/0962280214567140. Epub 2015 Jan 12.

11.

Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC).

Orlow I, Satagopan JM, Berwick M, Enriquez HL, White KA, Cheung K, Dusza SW, Oliveria SA, Marchetti MA, Scope A, Marghoob AA, Halpern AC.

Br J Dermatol. 2015 Apr;172(4):1081-9. doi: 10.1111/bjd.13467. Epub 2015 Feb 15.

12.

Blocking and randomization to improve molecular biomarker discovery.

Qin LX, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, Satagopan JM, Begg CB, Levine DA.

Clin Cancer Res. 2014 Jul 1;20(13):3371-8. doi: 10.1158/1078-0432.CCR-13-3155. Epub 2014 May 1.

13.

Factors associated with nevus volatility in early adolescence.

Oliveria SA, Scope A, Satagopan JM, Geller AC, Dusza SW, Weinstock MA, Berwick M, Bishop M, Marghoob AA, Halpern AC.

J Invest Dermatol. 2014 Sep;134(9):2469-2471. doi: 10.1038/jid.2014.189. Epub 2014 Apr 14. No abstract available.

14.

Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium.

Olson SH, Hsu M, Satagopan JM, Maisonneuve P, Silverman DT, Lucenteforte E, Anderson KE, Borgida A, Bracci PM, Bueno-de-Mesquita HB, Cotterchio M, Dai Q, Duell EJ, Fontham EH, Gallinger S, Holly EA, Ji BT, Kurtz RC, La Vecchia C, Lowenfels AB, Luckett B, Ludwig E, Petersen GM, Polesel J, Seminara D, Strayer L, Talamini R; Pancreatic Cancer Case-Control Consortium.

Am J Epidemiol. 2013 Sep 1;178(5):691-700. doi: 10.1093/aje/kwt052. Epub 2013 Jul 2.

15.

Evaluation of removable statistical interaction for binary traits.

Satagopan JM, Elston RC.

Stat Med. 2013 Mar 30;32(7):1164-90. doi: 10.1002/sim.5628. Epub 2012 Sep 27.

16.

Genetic terminology.

Elston RC, Satagopan JM, Sun S.

Methods Mol Biol. 2012;850:1-9. doi: 10.1007/978-1-61779-555-8_1.

17.

Prospective study of sunburn and sun behavior patterns during adolescence.

Dusza SW, Halpern AC, Satagopan JM, Oliveria SA, Weinstock MA, Scope A, Berwick M, Geller AC.

Pediatrics. 2012 Feb;129(2):309-17. doi: 10.1542/peds.2011-0104. Epub 2012 Jan 23.

18.

Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study.

Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, Capanu M, Stovall M, Smith SA, Wei S, Shore RE, Boice JD Jr, Lynch CF, Mellemkjaer L, Malone KE, Liang X; Wecare Study Collaborative Group, Haile RW, Concannon P, Bernstein JL.

Hum Mutat. 2012 Jan;33(1):158-64. doi: 10.1002/humu.21604. Epub 2011 Sep 29.

19.

Properties of preliminary test estimators and shrinkage estimators for evaluating multiple exposures - Application to questionnaire data from the SONIC study.

Satagopan JM, Zhou Q, Oliveria SA, Dusza SW, Weinstock MA, Berwick M, Halpern AC.

J R Stat Soc Ser C Appl Stat. 2011 Aug 1;60(4):619-632.

20.

Clinical and dermoscopic stability and volatility of melanocytic nevi in a population-based cohort of children in Framingham school system.

Scope A, Dusza SW, Marghoob AA, Satagopan JM, Braga Casagrande Tavoloni J, Psaty EL, Weinstock MA, Oliveria SA, Bishop M, Geller AC, Halpern AC.

J Invest Dermatol. 2011 Aug;131(8):1615-21. doi: 10.1038/jid.2011.107. Epub 2011 May 12.

21.

Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I.

J Transl Med. 2010 Jul 22;8:70. doi: 10.1186/1479-5876-8-70.

22.

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.

Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE.

Mod Pathol. 2010 Oct;23(10):1325-33. doi: 10.1038/modpathol.2010.120. Epub 2010 Jun 18.

23.

Normalization method for transcriptional studies of heterogeneous samples--simultaneous array normalization and identification of equivalent expression.

Qin LX, Satagopan JM.

Stat Appl Genet Mol Biol. 2009;8:Article 10. doi: 10.2202/1544-6115.1339. Epub 2009 Feb 4.

24.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

25.

Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count.

Oliveria SA, Satagopan JM, Geller AC, Dusza SW, Weinstock MA, Berwick M, Bishop M, Heneghan MK, Halpern AC.

Am J Epidemiol. 2009 Jan 1;169(1):41-53. doi: 10.1093/aje/kwn289. Epub 2008 Nov 10.

26.

Dermoscopic patterns of naevi in fifth grade children of the Framingham school system.

Scope A, Marghoob AA, Dusza SW, Satagopan JM, Agero AL, Benvenuto-Andrade C, Lieb JA, Weinstock MA, Oliveria SA, Geller AC, Halpern AC.

Br J Dermatol. 2008 May;158(5):1041-9. doi: 10.1111/j.1365-2133.2008.08510.x. Epub 2008 Mar 20.

PMID:
18363751
27.

Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.

Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, Diotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD.

Cancer Res. 2007 Oct 1;67(19):9591-6.

28.

Sequential quantitative trait locus mapping in experimental crosses.

Satagopan JM, Sen S, Churchill GA.

Stat Appl Genet Mol Biol. 2007;6:Article12. Epub 2007 Apr 17.

PMID:
17474878
29.

R/qtlDesign: inbred line cross experimental design.

Sen S, Satagopan JM, Broman KW, Churchill GA.

Mamm Genome. 2007 Feb;18(2):87-93. Epub 2007 Mar 8.

30.

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.

Maluf FC, Cordon-Cardo C, Verbel DA, Satagopan JM, Boyle MG, Herr H, Bajorin DF.

Ann Oncol. 2006 Nov;17(11):1677-86. Epub 2006 Sep 19.

PMID:
16984978
31.

Novel mutations of epidermal growth factor receptor in localized prostate cancer.

Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, Satagopan JM, Gerald WL, Scher HI, Lee P, Osman I.

Front Biosci. 2006 Sep 1;11:2518-25.

PMID:
16720329
32.

Quantitative trait locus study design from an information perspective.

Sen S, Satagopan JM, Churchill GA.

Genetics. 2005 May;170(1):447-64. Epub 2005 Mar 21.

33.

Two-stage designs for gene-disease association studies with sample size constraints.

Satagopan JM, Venkatraman ES, Begg CB.

Biometrics. 2004 Sep;60(3):589-97.

PMID:
15339280
34.

A note on competing risks in survival data analysis.

Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD.

Br J Cancer. 2004 Oct 4;91(7):1229-35. Review.

35.

Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.

Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K.

J Natl Cancer Inst. 2004 Jan 7;96(1):68-70.

PMID:
14709740
36.

Optimal two-stage genotyping in population-based association studies.

Satagopan JM, Elston RC.

Genet Epidemiol. 2003 Sep;25(2):149-57.

PMID:
12916023
37.

Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.

Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M.

Cancer Res. 2003 Apr 15;63(8):1759-63.

38.

BRCA1 and BRCA2 germline mutations in lymphoma patients.

Yossepowitch O, Olvera N, Satagopan JM, Huang H, Jhanwar S, Rapaport B, Boyd J, Offit K.

Leuk Lymphoma. 2003 Jan;44(1):127-31.

PMID:
12691152
39.

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH.

Blood. 2003 Sep 15;102(6):1989-96. Epub 2003 Apr 3.

40.

A statistical perspective on gene expression data analysis.

Satagopan JM, Panageas KS.

Stat Med. 2003 Feb 15;22(3):481-99. Review.

PMID:
12529876
41.

Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.

Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce HH, Kauff ND, Einat P, Jhanwar S, Satagopan JM, Oddoux C, Ellis N, Skaliter R, Yahalom J.

Clin Cancer Res. 2002 Dec;8(12):3813-9.

42.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

43.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15. Epub 2002 May 20.

44.

Two-stage designs for gene-disease association studies.

Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB.

Biometrics. 2002 Mar;58(1):163-70.

PMID:
11890312
45.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

46.

Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study.

Cheung IY, Cheung NK, Ghossein RA, Satagopan JM, Bhattacharya S, Coit DG.

Clin Cancer Res. 1999 Aug;5(8):2042-7.

47.

Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.

Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VV, Massagué J.

Cancer Res. 1998 Jul 1;58(13):2727-32.

48.

A bayesian approach to detect quantitative trait loci using Markov chain Monte Carlo.

Satagopan JM, Yandell BS, Newton MA, Osborn TC.

Genetics. 1996 Oct;144(2):805-16.

Supplemental Content

Loading ...
Support Center